HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
SCYX
SCYNEXIS, Inc.
There isn't enough reported data to score SCYX yet.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
SCYX Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Under pressure | |
| Under pressure | |
| Strong |
SCYX's revenue and balance sheet are currently healthy, but its profitability and cash flow are under pressure.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
SCYX PE Valuation
SCYX has no meaningful PE right now: it lost money over the past year.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
SCYX Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Moderate |
Analysts expect SCYX's losses to grow, with revenue declining.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
SCYX Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$1.44 | +$2.64 |
| Q2 2026 | -$2.09 | +$1.11 |
| Q1 2026 | -$3.84 | +$0.64 |
| Q4 2025 | -$1.36 | +$2.16 |
| Q3 2025 | -$4.08 | +$1.28 |
| Q2 2025 | -$3.20 | +$2.00 |
| Q1 2025 | -$4.48 | -127% |
| Q4 2024 | -$3.52 | -132% |
SCYX has the edge over HIMS on earnings, with more consistent year-over-year improvement.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS has the edge over SCYX on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS has the edge over SCYX on profitability, with a higher operating margin.
SCYX Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $235K | -83% |
| Q4 2025 | $18.6M | +1808% |
| Q3 2025 | $334K | -49% |
| Q2 2025 | $1.4M | +85% |
| Q1 2025 | $257K | -81% |
| Q4 2024 | $977K | -83% |
| Q3 2024 | $660K | -63% |
| Q2 2024 | $736K | -99% |
SCYX's revenue is growing: $0 last quarter, down 100% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -3309% | -2608 points |
| Q4 2025 | 56% | +881 points |
| Q3 2025 | -2516% | -953 points |
| Q2 2025 | -701% | +554 points |
| Q1 2025 | -3350% | -2658 points |
| Q4 2024 | -824% | -426 points |
| Q3 2024 | -1564% | -990 points |
| Q2 2024 | -1255% | -1344 points |
SCYX's operating margin was −3309% last quarter, up 42 points from the same quarter a year ago.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over SCYX on cash generation, producing positive trailing cash flow while its opponent burns cash.
SCYX Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$7.5M | +$1.3M |
| Q2 2026 | -$14.9M | -$7.4M |
| Q1 2026 | -$8.1M | -$636K |
| Q4 2025 | $18.4M | +$28.3M |
| Q3 2025 | -$8.7M | -1240% |
| Q2 2025 | -$7.5M | +$3.4M |
| Q1 2025 | -$7.5M | -$3.5M |
| Q4 2024 | -$9.9M | -$2.2M |
SCYX has burned cash in almost every quarter: −$12M over the past year, against −$34M the year before.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over SCYX on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
SCYX Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.2% | +18.8K shares |
| 1 year | +90% | +5.6M shares |
| 3 years | +90% | +5.6M shares |
| 5 years | +257% | +8.5M shares |
SCYX has 12M diluted shares, up 90% from a year ago.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
SCYX Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2024 | -0.5x | Net Cash |
| Q4 2023 | -0.5x | Net Cash |
| Q3 2023 | -0.6x | Net Cash |
| Q2 2023 | -0.9x | Net Cash |
SCYX has more cash than debt.
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
SCYX Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.2 | Neutral |
| Stochastic | 6.3 | Oversold |
SCYX's weekly RSI is 36 (neutral) and its Stochastic is 6 (oversold).
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
SCYX PE vs Healthcare Sector
| Metric | SCYX | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
SCYX has no meaningful PE right now: it lost money over the past year.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
SCYX Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $3.96 | 16% below |
| 20 week MA | $4.44 | 25% below |
| 50 week MA | $5.40 | 38% below |
| 100 week MA | $6.29 | 47% below |
| 200 week MA | $11.4 | 71% below |
SCYX is in a downtrend: it's below all five of its weekly moving averages, and 71% below its 200-week average.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS's yearly returns have swung widely, from +198% in 2024 to −56% in 2021. It's down 42% so far in 2026.
SCYX Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $69.8 | $57.1 | -18% |
| 2021 | $57.1 | $54.0 | -5.5% |
| 2022 | $54.0 | $12.5 | -77% |
| 2023 | $12.5 | $17.8 | +43% |
| 2024 | $17.8 | $7.99 | -55% |
| 2025 | $7.99 | $4.70 | -41% |
| 2026 YTD | $4.70 | $3.33 | -29% |
SCYX has the edge over HIMS on returns for 2026, with the stronger performance.